Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Basal Insulin GLP-1 RA Combination Therapy

This content area has six courses focused on Basal Insulin Analogues. Three of them are targeted at Primary Care Physicians and the other three at Diabetes specialists. All courses are open to all site visitors, you only need to register once and you will have access to the 3 Content areas and 10 courses at once. 

Each course is divided in different content modules that will be published along the coming months. Some of these modules are webcasts, case studies, articles, roundtable discussions or animated tables. After each module you will have a short quiz.


  • Unmet Needs and Rationale for Combination Therapies for Diabetes Specialists

    for Diabetes Specialists

    In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia. Sign up to the E-Alert to be updated on all new publications.

  • Unmet Needs and Rationale for Combination Therapies for Primary Care Physicians

    for Primary Care Physicians

    In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia. After completing this course, you will be able to identify patients for whom basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and also learn some practical tips on how to best manage these patients. Sign up to the E-Alert to be updated on all new publications.

  • Efficacy and Safety for Diabetes Specialists

    for Diabetes Specialists

    The purpose of this course is to learn how the efficacy and safety of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy surpasses that of the individual components. Participants will learn how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.

  • Efficacy and Safety for Primary Care Physicians

    for Primary Care Physicians

    In this course you will learn about basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and how the efficacy and safety of this approach surpasses that of the individual components. The course will provide information on how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.

  • Convenience, Compliance and Overcoming Clinical Inertia for Diabetes Specialists

    for Diabetes Specialists

    This course reviews the practical aspects of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and shows how fixed-dose combination therapies provide added convenience that may help overcome clinical inertia related to insulin initiation and intensification. Clinical data will be presented to demonstrate how the efficacy and safety of basal insulin–GLP-1 receptor agonist combination therapy surpasses that of the individual components. After completing the course, participants will be able to identify patients for whom treatment with basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and know how to best manage these patients. Sign up to the E-Alert to be updated on all new publications.

  • Convenience, Compliance and Overcoming Clinical Inertia for Primary Care Physicians

    for Primary Care Physicians

    This course reviews the practical aspects of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and shows how fixed-dose combination therapies provide added convenience that may help overcome clinical inertia related to insulin therapy. Clinical data will be presented to demonstrate how the efficacy and safety of basal insulin–GLP-1 receptor agonist combination therapy surpasses that of the individual components. After completing the course, participants will be able to identify patients for whom treatment with basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and know how to best manage these patients.

Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.


Search this site

Search form


 

Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk